Taysha Gene Therapies, Inc.
$5.55
-2.5%Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -16.3).
Valuation inputs: P/E -16.3, earnings yield N/A, momentum -2.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -44.1%, ROIC -34.9%).
Profitability stack: net margin -11.2%, ROE -44.1%, ROIC -34.9%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +28.1%, momentum -2.5%, net margin -11.2%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Taysha Gene Therapies, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Taysha Gene Therapies, Inc. Fair Value Envelope
Taysha Gene Therapies, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Taysha Gene Therapies, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Taysha Gene Therapies, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Taysha Gene Therapies, Inc. Street Expectations Map
Wall Street analysts project that TSHA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 11.50, with estimates ranging from a low of 11.00 to a high of 13.00.
The consensus 1-year price target stands at 11.50, with estimates ranging from a low of 11.00 to a high of 13.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Taysha Gene Therapies, Inc. Insider Positioning
During the last 12 months, insiders have purchased $29K and sold $5.41M worth of TSHA shares, resulting in $5.38M of net selling activity.
3 Months
0
0.00
200.0K
892.00K
-892K
-$892K
3-6 Months
0
0.00
598.6K
2.82M
-2.8M
-$2.82M
6-9 Months
41.1K
28.76K
370.2K
1.70M
-1.7M
-$1.67M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Nagendran Sukumar
Director, Officer: President And Head Of R&D
$29K
Top Sellers
Nagendran Sukumar
Director, Officer: President And Head Of R&D
$4.08M
Nolan Sean P.
Director, Officer: Chief Executive Officer
$840K
Alam Kamran
Officer: Chief Financial Officer
$493K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $5.38M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
TSHA has not reported any dividend yield values in the available annual periods.
tsha Dividend History
Learning Layer
Related Guides
Build conviction on TSHA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.